Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

e-Therapeutics to Raise £40 Million

Published: Tuesday, February 12, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
Company to advance lead cancer drug and exploit network pharmacology platform.

e-Therapeutics plc proposes to raise GBP 40 million (approximately GBP 39 million net) through an issue of new ordinary shares to existing and new institutional investors.

The new shares will be priced at 32p, a premium of 4% to the closing mid-market price on the last dealing day before this announcement.

Irrevocable undertakings of support have been received from shareholders representing approximately 86% of the Company’s equity in advance of a general meeting where approval for the issue will be sought.

Following the proposed issue, the Company will have pro-forma net cash and liquid resources of approximately GBP 48 million.

Together with expected receipts from R&D tax credits and interest, these resources are intended to support all of the Company’s currently planned discovery and development activities into 2017, by which time the Directors believe an out-licensing deal could be concluded for the Company’s lead cancer drug, ETS2101.

The principal planned uses of the Company’s enlarged cash resources are:

• to complete phase I trials for ETS2101 and advance the drug seamlessly into and through the next phase of its clinical development, which is expected to include a randomized phase II trial in brain cancer (glioma) and a phase Ib/II trial that will explore the drug’s activity in four to six other cancer indications. e-Therapeutics plans to spend around GBP 25 million on this programme for ETS2101 and expects to complete the studies in time to conclude a licensing deal or deals during 2017 if the data are supportive;

• to continue investment in new drug discovery using the Company’s network pharmacology platform. The Directors are confident that sustained investment in the platform and its application to drug discovery will yield new drug candidates that will drive future value in the business; and

• to advance newly discovered drugs and existing product assets into and through preclinical and clinical development, with the aim of building an increasingly diverse and mature portfolio of drug candidates.

Professor Malcolm Young, Chief Executive Officer of e-Therapeutics, said: “We appreciate the continuing support of existing investors and are also pleased to have attracted significant new investors to the Company. With our financial position secure we are well placed to build further shareholder value based on our innovative platform and product portfolio.”

Dr Daniel Elger, Chief Financial Officer of e-Therapeutics, added: “This fundraising provides us with the resources needed for significant investment in new drug discovery and to take our lead cancer drug ETS2101 through efficacy-focused trials that could lead to a lucrative licensing deal.”

The funds to be raised through the new issue will include a substantial further investment by Invesco Asset Management Limited, whose shareholding will increase from 45.92% to 49.90% after completion.

The Takeover Panel has granted an Accelerated Rule 9 Waiver in respect of the acquisition of new shares by Invesco.

A circular to shareholders, including a notice convening a general meeting, will be dispatched shortly.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

e-Therapeutics Reports Positive Interim Results from UK Phase Ia Trial of ETS2101
ETS2101 well tolerated at all six dose escalations with no serious adverse events attributed to the drug.
Tuesday, April 01, 2014
e-Therapeutics Starts Phase IIb Trial of ETS6103 in Major Depressive Disorder
Company expects to report the results of the trial in the first half of 2015.
Thursday, October 31, 2013
e-Therapeutics Starts Second Phase I Cancer Trial of ETS2101
Trial will enrol up to 45 patients with solid tumours at UK centres.
Friday, February 01, 2013
e-Therapeutics Provides Update on Progress of ETS2101 Cancer Trials
Interim data from the trials are expected in H1 2013.
Monday, December 24, 2012
e-Therapeutics’ ETS2101 Enters Phase I Clinical Trial in Brain Cancer
First findings are expected in late 2012.
Wednesday, June 20, 2012
e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2012
Further drugs for infection and depression expected to enter trials in 2012.
Friday, June 15, 2012
Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
Enrolment of patients into trials will begin shortly.
Thursday, March 29, 2012
e-Therapeutics Outlines Goals for 2012
Company announces presentation at biotech showcase conference.
Thursday, March 01, 2012
Scientific News
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!